** Shares of cancer drug developer MAIA Biotechnology MAIA.A rise 16.4% to $2.20
** Co says its experimental drug, THIO, helped patients with a type of lung cancer live for a median of 16.9 months, in mid-stage trial
** THIO was generally well-tolerated in patients who had received multiple previous treatments, co says
** Co says it is considering the possibility of accelerated FDA approval of THIO
** THIO gained 66.4% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.